Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:11 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Comparison of Insulin Therapy in Treating Post-Transplant Diabetes
NCT01963728 · Inova Health Care Services · PHASE4 · terminated · last registry update 2022-07-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Blood sugar status of the enrolled subjects wasn't evaluable” | – | Registry record, Inova Health Care Services |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against INSR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-04-21Phase 3 first posted: Novo Nordisk A/S, Insulin Icodec (NCT05823948)
- 2023-04-14Phase 3 first posted: Novo Nordisk A/S, Insulin Icodec + Semaglutide (NCT05813912)
- 2023-04-07Phase 3 first posted: Sunshine Lake Pharma Co., Ltd., Insulin Degludec and Insulin Aspart (NCT05802862)
- 2023-03-14Phase 3 first posted: Hospital Universitario San Ignacio, insulin degludec + liraglutide + Insulin Glargine - Insulin Aspart (NCT05767255)
- 2023-02-08Results posted on the registry: Eli Lilly and Company, LY900014 + Insulin Lispro (NCT03952130)
- 2022-12-07Phase 3 first posted: Huashan Hospital, Insulin Degludec and Insulin Aspart (NCT05641337)
- 2022-11-14Results posted on the registry: Sanofi, Insulin glargine, 300 U/ml + Insulin degludec, 100U/ml (NCT04075513)
- 2022-11-02Results posted on the registry: Eli Lilly and Company, LY3209590 + Insulin Degludec (NCT04450394)
- 2022-10-27Results posted on the registry: Eli Lilly and Company, LY3209590 + Insulin Degludec (NCT04450407)
- 2022-10-04Phase 3 first posted: Jaime Daniel Mondragon, Dapagliflozin 10mg Tab + Statins (Cardiovascular Agents) (NCT05565976)
- 2022-09-19Phase 3 first posted: Xiangya Hospital of Central South University, metformin+empagliflozin+insulin glargine + IDegLira (NCT05545800)
- 2022-07-21Results posted on the registry: Azienda Ospedaliero-Universitaria Careggi, a drug against INSR (NCT03557892)
- 2022-07-19Phase 3 first posted: Eli Lilly and Company, Insulin Efsitora Alfa + Insulin Degludec (NCT05463744)
- 2022-07-18Phase 3 first posted: Universidad Panamericana, Insulin (NCT05461365)
- 2022-06-10Phase 3 first posted: Sanofi, Insulin glargine/Lixisenatide + IDegAsp (NCT05413369)
- 2022-06-08Results posted on the registry: Sansum Diabetes Research Institute, Insulin LISPRO + Insulin, Long-Acting and Insulin (NCT01613807)
- 2022-06-03Results posted on the registry: Eli Lilly and Company, LY900014 + Insulin Degludec (NCT04585776)
- 2022-06-02Results posted on the registry: Sansum Diabetes Research Institute, Insulin Degludec + Insulin Glargine (NCT03668808)
- 2022-05-05Phase 3 first posted: Eli Lilly and Company, Insulin Efsitora Alfa + Insulin Degludec (NCT05362058)
- 2022-04-29Phase 3 first posted: Novo Nordisk A/S, IcoSema + Insulin icodec (NCT05352815)
- 2022-04-27Results posted on the registry: Novo Nordisk A/S, Insulin degludec + Insulin Aspart (NCT03377699)
- 2022-04-07Also stopped (terminated): Sanofi, Insulin glargine, 300 units per milliliter (U/mL) + Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra) (NCT03260868)
- 2022-03-31Results posted on the registry: Emory University, Degludec + Glargine (NCT03336528)
- 2022-03-11Phase 3 first posted: Sling Therapeutics, Inc., Linsitinib + Placebo (NCT05276063)
- 2022-03-11Phase 3 first posted: Eli Lilly and Company, Insulin Efsitora Alfa + Insulin Degludec (NCT05275400)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision